Durvalumab not cost‐effective with current pricing strategies for stage III NSCLC

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Author:	Mary Beth Nierengarten
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Cancer
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Internet